Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.

Original languageEnglish (US)
Pages (from-to)757-762
Number of pages6
JournalVeterinary Pathology
Volume23
Issue number6
StatePublished - Nov 1986

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.'. Together they form a unique fingerprint.

Cite this